KM made pretty clear in the last conference call that Amarin is ready to release its own generic Vascepa whenever the conditions warrant doing so. I know nothing about the process, but I do wonder what happens to brand Vascepa if an Amarin generic version is released. Does the brand product vanish? If so, I'm sure the company has to be very careful. Its current 60 percent share of the market is enough to break even most quarters. I worry that the generic version would have trouble competing against other generics. Don't the generic companies have deals with pharmacies and insurers to favor their generic products over competitors?
Market Data 
Markets 
AI
